Companies
Gilead Sciences
antiviral biologic leader (HIV, hepatitis) that extended into cell therapy through its Kite Pharma division.
- Country
- United States
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headquarters | Foster City, California, United States | sec.gov |
| Production site | Foster City, California; La Verne, California; El Segundo, California; Santa Monica, California; Frederick, Maryland; Cork, Ireland; Dublin, Ireland; Hoofddorp, Netherlands; Edmonton, Canada; Oceanside, California | sec.gov |
| Headcount | 17,000 employees as of 2025 | s29.q4cdn.com · sec.gov |
| Certification | ISO 15001 (Cork facility); TRUE-certified to the Gold level (Foster City campus, Cork facility) medium confidence | gilead.com |
| Capacity | Over 24,000 potential manufacturing capacity by 2026 (projected) medium confidence | s29.q4cdn.com |
Independent sources: s29.q4cdn.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Antibody-drug conjugates (ADCs) | therapeutics-platforms | High | → |
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.